These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38136333)

  • 1. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy.
    Cedres S; Valdivia A; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Assaf-Pastrana JD; Felip E; Garrido P
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
    Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.
    Reveneau MF; Masliah-Planchon J; Fernandez M; Ouikene A; Dron B; Dadamessi I; Dayen C; Golmard L; Chauffert B
    Front Oncol; 2024; 14():1410322. PubMed ID: 39091916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tsunami of immunotherapy reaches mesothelioma.
    Mielgo-Rubio X; Cardeña Gutiérrez A; Sotelo Peña V; Sánchez Becerra MV; González López AM; Rosero A; Trujillo-Reyes JC; Couñago F
    World J Clin Oncol; 2022 Apr; 13(4):267-275. PubMed ID: 35582652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Malignant Pleural Mesothelioma.
    de Gooijer CJ; Borm FJ; Scherpereel A; Baas P
    Front Oncol; 2020; 10():187. PubMed ID: 32154179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.
    Nicolini F; Bocchini M; Bronte G; Delmonte A; Guidoboni M; Crinò L; Mazza M
    Front Oncol; 2019; 9():1519. PubMed ID: 32039010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma.
    Rondon L; Fu R; Patel MR
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
    Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
    Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
    Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
    Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Immunotherapy of Malignant Pleural Mesothelioma.
    Liao D; Yu Y; Mei Q; Wang Z; Li X; Jia Y; Kong F
    Onco Targets Ther; 2021; 14():4477-4484. PubMed ID: 34429612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
    Katzman D; Sterman DH
    Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.